[Preoperation risk factor analysis in orthotopic liver transplantation with pre-transplant artificial liver support therapy].
OBJECTIVE
Orthotopic liver transplantation (OLT) is an accepted therapy for selected patients with advanced liver diseases. However, the early mortality rate after OLT remains relatively high due to the poor selection of candidates with various serious conditions. The aim of this study is to assess the value of pretransplantation artificial liver support treatment in reducing the pre-operation risk factors relating to early mortality after OLT.


METHODS
50 adult patients in various stages of different etiologies who underwent OLT procedures had been treated with molecular adsorbent recycling system (MARS) preoperatively. The study was designed in two parts: the first one was to evaluate the effectiveness of a single MARS therapy by using some clinical and laboratory parameters which were supposed to be therapeutical pretransplantation risk factors. The second part was to study the patients undergoing OLT by using the regression analysis on preoperation risk factors relating to early (within 30 d after OLT) mortality rate.


RESULTS
Among the 50 patients, a statistically significant improvement of the biochemical parameters was observed (pretreatment vs posttreatment). 8 patients cancelled their scheduled LTXs due to significant improvements in their clinical conditions or recovery of their failing liver functions. 8 patients died and 34 patients successfully underwent LTX. The immediate outcome (within 30 postoperative days) of these 34 patients was that 28 were kept alive and 6 died.


CONCLUSIONS
Preoperation sequential organ failure assessment (SOFA), level of creatinine, INR, TNFalpha, and IL-10 are the main preoperative risk factors relating to early death after an operation. MARS treatment before a transplant operation can relieve these factors significantly, hence improve survival rate of liver transplantation or even make the transplantation unnecessary.
Yuan
Jin-zhong
JZ
Xiangya Transplantation Medical Academy, Central South University, Changsha 410013, China. yuanjz1229@vip.sina.com.cn
Ye
Qi-fa
QF
Ming
Ying-zi
YZ
Hang
Zu-fa
ZF
Zhao
Ling-ling
LL
Zhao
Xue-yi
XY
Wang
Min-min
MM
Zhang
Mao-zu
MZ
Wen
Zhi-xiang
ZX
Zhu
Shai-hong
SH
Wu
Kun
K
D000368:Aged; D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D008103:Liver Cirrhosis / Q000601:surgery*; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation / Q000379:methods; D019164:Liver, Artificial; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D012307:Risk Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10